{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Leukemia+Myelogenous&page=5",
    "query": {
      "condition": "Chronic Leukemia Myelogenous",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 1233,
    "total_pages": 124,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Leukemia+Myelogenous&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Leukemia+Myelogenous&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T10:54:30.761Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00644878",
      "title": "Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia - Chronic Phase"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2008-10",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2021-08-18",
      "last_synced_at": "2026-10-02T10:54:30.761Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Augusta, Georgia • Beech Grove, Indiana + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Beech Grove",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00644878"
    },
    {
      "nct_id": "NCT00660920",
      "title": "Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia",
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "Ponatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ariad Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2008-06",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2018-05-16",
      "last_synced_at": "2026-10-02T10:54:30.761Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Ann Arbor, Michigan • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00660920"
    },
    {
      "nct_id": "NCT02258490",
      "title": "Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Chronic Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "G-CSF mobilized CD34+ selected cells for transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "17 Years to 75 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-03-15",
      "last_synced_at": "2026-10-02T10:54:30.761Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02258490"
    },
    {
      "nct_id": "NCT01772420",
      "title": "Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Myelodysplastic Syndrome",
        "Anemia",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Eltrombopag Olamine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2012-10",
      "completion_date": "2020-07-09",
      "has_results": true,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-10-02T10:54:30.761Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas • The Bronx, New York",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01772420"
    },
    {
      "nct_id": "NCT00123474",
      "title": "Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myeloid Leukemia, Chronic, Chronic-Phase"
      ],
      "interventions": [
        {
          "name": "dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 724,
      "start_date": "2005-07",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-08-25",
      "last_synced_at": "2026-10-02T10:54:30.761Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Alhambra, California • Anaheim, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00123474"
    },
    {
      "nct_id": "NCT00967525",
      "title": "Intraosseous Infusion of Unrelated Cord Blood Grafts",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "cord blood infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "36 Months",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "36 Months to 60 Years"
      },
      "enrollment_count": 5,
      "start_date": "2007-03",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2013-11-27",
      "last_synced_at": "2026-10-02T10:54:30.761Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00967525"
    },
    {
      "nct_id": "NCT06159491",
      "title": "Pacritinib in CMML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Pacritinib",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Douglas Tremblay",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2024-09-18",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-02T10:54:30.761Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06159491"
    },
    {
      "nct_id": "NCT00081874",
      "title": "RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Mantle Cell Lymphoma",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 29,
      "start_date": "2004-04",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-02T10:54:30.761Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081874"
    },
    {
      "nct_id": "NCT01890486",
      "title": "The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Non-Hodgkin's Lymphoma",
        "Hodgkin's Disease",
        "Multiple Myeloma",
        "Germ Cell Neoplasms",
        "Myelodysplastic Syndromes",
        "Chronic Lymphocytic Leukemia",
        "Immunodeficiency Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 2000,
      "start_date": "2001-05-21",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-02T10:54:30.761Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01890486"
    },
    {
      "nct_id": "NCT06088888",
      "title": "TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "TGRX-678",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shenzhen TargetRx Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2024-07-02",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-10-02T10:54:30.761Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06088888"
    }
  ]
}